Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership

Kite, a Gilead Company, will use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology platform in a global oncology cell therapy collaboration that could generate up to $3.16 billion-plus for Sangamo, the companies said today.Kite plans to modify genes through Sangamo's ZFN technology in order to develop autologous and allogeneic next-generation cell therapies for different cancers. Those cell therapies would be “ ex vivo ”; cells would be removed from the b